Literature DB >> 17660931

Substance abuse and quality of life among severely mentally ill consumers: a longitudinal modelling analysis.

Karen A Urbanoski1, John Cairney, Edward Adlaf, Brian Rush.   

Abstract

BACKGROUND: Evidence suggests that substance abuse negatively affects both psychiatric symptom severity and quality of life (QOL) in people with severe mental illness (SMI). However, these relationships have not been examined simultaneously, nor have they been characterized over time. Thus, it is difficult to appreciate the extent to which substance abuse exerts an enduring effect on psychiatric symptoms and distress and/or QOL in this population. The purpose of this study is to test a conceptual model linking these factors together.
METHODS: Subjects were participants in a longitudinal evaluation of community mental healthcare in Ontario (n = 133). Comprehensive consumer assessments were conducted at treatment entry, and at 9 and 18 months. Subjects were receiving intensive case management or assertive community treatment throughout the 18-month study period. Structural equation modelling was used to examine the concurrent and longitudinal relationships between substance abuse, symptoms and distress, and QOL.
RESULTS: The prevalence of substance abuse was 55.0%. The SEM analysis suggested that substance abuse at baseline was associated with elevated symptomatology and distress and lower QOL, and that these effects endured after 18 months of treatment. Psychiatric symptoms and distress mediated the negative relationship between substance abuse and QOL.
CONCLUSIONS: The mediating role played by symptom and distress levels in the relationship between substance abuse and QOL suggests the importance of closely monitoring changes in these factors among SMI patients with substance problems. Tracking symptom severity and distress levels over time will allow service providers to intervene and potentially improve the QOL of individuals with SMI.

Entities:  

Mesh:

Year:  2007        PMID: 17660931     DOI: 10.1007/s00127-007-0236-6

Source DB:  PubMed          Journal:  Soc Psychiatry Psychiatr Epidemiol        ISSN: 0933-7954            Impact factor:   4.328


  26 in total

1.  Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study.

Authors:  D A Regier; M E Farmer; D S Rae; B Z Locke; S J Keith; L L Judd; F K Goodwin
Journal:  JAMA       Date:  1990-11-21       Impact factor: 56.272

2.  Psychiatric symptoms in mentally ill chemical abusers.

Authors:  M P Carey; K B Carey; A W Meisler
Journal:  J Nerv Ment Dis       Date:  1991-03       Impact factor: 2.254

Review 3.  Substance abuse treatment for people with schizophrenia.

Authors:  A S Bellack; J S Gearon
Journal:  Addict Behav       Date:  1998 Nov-Dec       Impact factor: 3.913

4.  Psychopathology and quality of life in schizophrenia.

Authors:  S Packer; J Husted; S Cohen; G Tomlinson
Journal:  J Psychiatry Neurosci       Date:  1997-07       Impact factor: 6.186

5.  The drug abuse screening test.

Authors:  H A Skinner
Journal:  Addict Behav       Date:  1982       Impact factor: 3.913

6.  Use of the AUDIT and the DAST-10 to identify alcohol and drug use disorders among adults with a severe and persistent mental illness.

Authors:  S A Maisto; M P Carey; K B Carey; C M Gordon; J R Gleason
Journal:  Psychol Assess       Date:  2000-06

7.  Quality of life assessments by adult substance abusers receiving publicly funded treatment in Massachusetts.

Authors:  Kevin W Smith; Mary Jo Larson
Journal:  Am J Drug Alcohol Abuse       Date:  2003-05       Impact factor: 3.829

8.  Longitudinal assessment of quality of life in acute psychiatric inpatients: reliability and validity.

Authors:  J Russo; P Roy-Byrne; D Reeder; M Alexander; E Dwyer-O'Connor; C Dagadakis; R Ries; D Patrick
Journal:  J Nerv Ment Dis       Date:  1997-03       Impact factor: 2.254

9.  Alcohol use and abuse in schizophrenia. A prospective community study.

Authors:  R E Drake; F C Osher; M A Wallach
Journal:  J Nerv Ment Dis       Date:  1989-07       Impact factor: 2.254

10.  Relationship of cocaine and other substance dependence to well-being of high-risk psychiatric patients.

Authors:  B E Havassy; P G Arns
Journal:  Psychiatr Serv       Date:  1998-07       Impact factor: 3.084

View more
  6 in total

Review 1.  Variations in rates of comorbid substance use in psychosis between mental health settings and geographical areas in the UK. A systematic review.

Authors:  Giuseppe Carrà; Sonia Johnson
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2008-11-13       Impact factor: 4.328

2.  Secondary prevention of hazardous alcohol consumption in psychiatric out-patients: a randomised controlled study.

Authors:  Sophia Eberhard; Göran Nordström; Peter Höglund; Agneta Ojehagen
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2009-03-18       Impact factor: 4.328

3.  The relationship between chronic pain and health-related quality of life in long-term social assistance recipients in Norway.

Authors:  Borghild Løyland; Christine Miaskowski; Steven M Paul; Espen Dahl; Tone Rustøen
Journal:  Qual Life Res       Date:  2010-07-22       Impact factor: 4.147

4.  Current quality of life and its determinants among opiate-dependent individuals five years after starting methadone treatment.

Authors:  Jessica De Maeyer; Wouter Vanderplasschen; Jan Lammertyn; Chijs van Nieuwenhuizen; Bernard Sabbe; Eric Broekaert
Journal:  Qual Life Res       Date:  2010-08-26       Impact factor: 4.147

5.  Comparison of health-related quality of life among men with different co-existing severe mental disorders in treatment for substance use.

Authors:  Ana Adan; Julia E Marquez-Arrico; Gail Gilchrist
Journal:  Health Qual Life Outcomes       Date:  2017-10-23       Impact factor: 3.186

6.  Health-related quality of life in outpatients with substance use disorder: evolution over time and associated factors.

Authors:  Melexima Simirea; Cédric Baumann; Michael Bisch; Hélène Rousseau; Paolo Di Patrizio; Sarah Viennet; Stéphanie Bourion-Bédès
Journal:  Health Qual Life Outcomes       Date:  2022-02-16       Impact factor: 3.186

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.